Objective: To review available literature evaluating the pharmacology, pharmacokinetics, clinical efficacy, and adverse effects of cilomilast, a selective phosphodiesterase-4 (PDE4) inhibitor.

1 Nitric oxide is a potent vasodilator, as it generates cyclic guanosine-5-monophosphate (cGMP). As cGMP is principally hydrolysed by phosphodiesterase-5 A (PDE-5 A), PDE-5 inhibitors potentiate the ...

PDE2 (phosphodiesterase 2) is upregulated in human heart failure. Cardiac PDE2‐transgenic mice are protected against contractile dysfunction and arrhythmias in heart failure but whether an acute ...

Viagra improves erections in over 80% of men taking 100 mg, it takes an average of 36 minutes to work, with effects lasting ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...

The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow ...

Medications to treat ED are exceedingly popular, with sildenafil (sold under the more commonly known brand name Viagra) being ...

Researchers were originally studying sildenafil as a potential treatment for high blood pressure. However, during clinical ...

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...